利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.016 秒)

    Transdermal drug delivery device
    2.
    发明授权
    Transdermal drug delivery device 失效
    透皮给药装置

    公开(公告)号：US4781924A

    公开(公告)日：1988-11-01

    申请号：US118577

    申请日：1987-11-09

    申请人： Eun S. Lee ,  Su I. Yum

    发明人： Eun S. Lee ,  Su I. Yum

    IPC分类号： A61K9/70 ,  A61M37/00 ,  A61F13/00

    CPC分类号： A61K9/7084

    摘要： A diffusional drug delivery device is described which can provide for stability of the adhesive and system components, elimination of the initial burst of drug and hence irritation, and to provide for delayed onset of therapeutic effect along with delivery of a therapeutic agent at an optimum rate. The therapeutic agent in a first form which is suitable for storage, and the anhydrous activating means are inert when in an anhydrous environment. Moisture activates the system whereby the activating means provides an acidic or basic solution and the first form of the therapeutic agent is converted to a second form which is suitable for absorption through the skin or mucosa.

    Transdermal administration of oxybutynin
    4.
    发明授权
    Transdermal administration of oxybutynin 失效
    透皮给药奥昔布宁

    公开(公告)号：US5411740A

    公开(公告)日：1995-05-02

    申请号：US193661

    申请日：1994-02-08

    申请人： Eun S. Lee ,  Diane E. Nedberge ,  Su I. Yum

    发明人： Eun S. Lee ,  Diane E. Nedberge ,  Su I. Yum

    IPC分类号： A61K9/00 ,  A61K9/70 ,  A61K31/135 ,  A61K31/215 ,  A61K31/216 ,  A61K47/10 ,  A61K47/14 ,  A61K47/34 ,  A61P13/02 ,  A61P15/00 ,  A61P25/00 ,  A61F13/02

    CPC分类号： A61K9/7053 ,  A61K31/215 ,  A61K31/216 ,  A61K47/14 ,  A61K9/0014 ,  A61K9/7084 ,  Y10S514/946

    摘要： The present invention is directed to the transdermal administration of oxybutynin together with a suitable permeation enhancer. The invention includes a transdermal drug delivery device comprising a matrix adapted to be placed in oxybutynin- and permeation enhancer-transmitting relation with the skin site. The matrix contains sufficient amounts of a permeation enhancer and of oxybutynin, in combination, to continuously administer to the skin for a predetermined period of time the oxybutynin to provide an effective therapeutic result. The invention is also directed to a method for the transdermal administration of a therapeutically effective amount of oxybutynin together with a skin permeation-enhancing amount of a suitable permeation enhancer.

    摘要翻译： 本发明涉及奥昔布宁与合适的渗透增强剂的透皮给药。 本发明包括透皮药物递送装置，其包含适于与皮肤部位置于奥昔布宁和渗透增强剂 - 传递关系中的基质。 基质含有足量的渗透促进剂和奥昔布宁组合，以持续给予皮肤预定的时间，奥昔布宁提供有效的治疗结果。 本发明还涉及用于透皮给药治疗有效量的奥昔布宁以及皮肤渗透增强剂量的合适的渗透增强剂的方法。

    Abusable substance dosage form having reduced abuse potential
    6.
    发明授权
    Abusable substance dosage form having reduced abuse potential 失效
    可吸收的物质剂量形式具有减少的吸收潜力

    公开(公告)号：US5236714A

    公开(公告)日：1993-08-17

    申请号：US265738

    申请日：1988-11-01

    申请人： Eun S. Lee ,  Victor Goetz

    发明人： Eun S. Lee ,  Victor Goetz

    IPC分类号： A61K9/00 ,  A61K9/70 ,  A61K31/445 ,  A61K31/485 ,  A61K45/06 ,  A61K47/06 ,  A61P25/30

    CPC分类号： B09B3/0075 ,  A61K31/445 ,  A61K31/485 ,  A61K9/0004 ,  A61K9/7084 ,  B09B2220/14

    摘要： Compositions and dosage forms for administering abusable substances are disclosed which have a reduced potential for abuse without diminishing the therapeutic or beneficial effects of the abusable substance. Topical compositions for application to the skin or mucosa contain the abusable substance in a form which is permeable to the skin or mucosa to which it is to be applied and an antagonist for the abusable substance is present in the composition in an abuse negating amount and in a form that is impermeable to the skin or mucosa to which the composition is to be applied. Controlled release dosage forms which release the abusable substance from a drug reservoir composition confined behind a release rate controlling barrier have the abusable substance and its antagonist in the drug reservoir. The abusable substance is present in a form that is releasable from the dosage form and the antagonist is present in an abuse negating amount in a form that is not releasable from the dosage form. Thus the compositions and dosage forms of this invention permit the therapeutic use, at substantially full potency, of an abusable substance when use as prescribed but reduce the abuse potential of the compositions and dosage forms by other routes of administration. Preferred embodiments of the invention utilize fentanyl as the abusable substance and naltrexone as the antagonist in a transdermal dosage form.

    摘要翻译： 公开了用于施用可滥用物质的组合物和剂型，其具有降低的滥用可能性，而不会降低可滥用物质的治疗或有益效果。 适用于皮肤或粘膜的局部组合物含有对其要施用的皮肤或粘膜可渗透的形式的可滥用物质，并且可滥用物质的拮抗剂以滥用消除量存在于组合物中 对于要施用组合物的皮肤或粘膜不透水的形式。 从限制在释放速率控制屏障之后的药物储库组合物释放可滥用物质的控制释放剂型在药物储库中具有可滥用物质及其拮抗剂。 可滥用物质以可从剂型释放的形式存在，并且拮抗剂以不能从剂型释放的形式以滥用消除量存在。 因此，当按照规定使用时，本发明的组合物和剂型允许基本上全部效力治疗可使用的物质，但是通过其它给药途径降低组合物和剂型的滥用潜力。 本发明的优选实施方案以透皮剂量形式使用芬太尼作为可滥用物质和纳曲酮作为拮抗剂。

    Transdermal drug delivery device
    7.
    发明授权
    Transdermal drug delivery device 失效
    透皮给药装置

    公开(公告)号：US4837027A

    公开(公告)日：1989-06-06

    申请号：US230211

    申请日：1988-08-09

    申请人： Eun S. Lee ,  Su I. Yum

    发明人： Eun S. Lee ,  Su I. Yum

    IPC分类号： A61K9/70

    CPC分类号： A61K9/7053 ,  A61K9/7084

    摘要： A diffusional drug delivery device is described which can provide for stability of the adhesive and system components, elimination of the initial burst of drug and hence irritation, and to provide for delayed onset of therapeutic effect along with delivery of a therapeutic agent at an optimum rate. The therapeutic agent in a first form which is suitable for storage, and the anhydrous activating means are inert when in an anhydrous environment. Moisture activates the system whereby the activating means provides an acidic or basic solution and the first form of the therapeutic agent is converted to a second form which is suitable for absorption through the skin or mucosa.

    摘要翻译： 描述了扩散药物递送装置，其可以提供粘合剂和系统组分的稳定性，消除药物的初始爆发并因此刺激，并且提供治疗效果的延迟开始以及以最佳速率递送治疗剂 。 适于储存的第一种形式的治疗剂和无水活化装置在无水环境中是惰性的。 水分激活系统，由此激活装置提供酸性或碱性溶液，并且将第一形式的治疗剂转化为适合于通过皮肤或粘膜吸收的第二种形式。